Shares of Thermo Fisher Scientific Inc (NYSE:TMO) have been assigned a consensus recommendation of “Buy” from the eighteen research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, sixteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $188.56.

A number of research analysts have weighed in on the stock. Bank of America Corporation raised their price objective on shares of Thermo Fisher Scientific from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, May 9th. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Jefferies Group LLC raised their price objective on shares of Thermo Fisher Scientific from $160.00 to $175.00 and gave the company a “hold” rating in a research note on Friday, April 28th. BidaskClub lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 27th. Finally, Citigroup Inc. reaffirmed a “buy” rating and issued a $201.00 price objective (up from $182.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 10th.

Shares of Thermo Fisher Scientific (NYSE:TMO) traded up 0.87% during midday trading on Friday, reaching $173.23. 2,202,642 shares of the company’s stock traded hands. The stock has a market cap of $67.58 billion, a P/E ratio of 30.18 and a beta of 1.06. Thermo Fisher Scientific has a 12 month low of $139.07 and a 12 month high of $182.87. The stock has a 50 day moving average of $176.78 and a 200-day moving average of $165.46.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The business had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. During the same period last year, the company posted $2.03 earnings per share. The business’s quarterly revenue was up 10.2% on a year-over-year basis. On average, equities research analysts forecast that Thermo Fisher Scientific will post $9.24 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is currently 10.45%.

In related news, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $176.26, for a total transaction of $440,650.00. Following the completion of the sale, the chief financial officer now owns 37,790 shares in the company, valued at $6,660,865.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 20,000 shares of the firm’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the sale, the chief executive officer now owns 269,279 shares of the company’s stock, valued at approximately $46,528,718.41. The disclosure for this sale can be found here. Insiders have sold 27,188 shares of company stock worth $4,702,223 over the last three months. 0.49% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. increased its stake in Thermo Fisher Scientific by 2,692.1% in the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after buying an additional 22,165,530 shares during the period. C WorldWide Group Holding A S increased its stake in Thermo Fisher Scientific by 997.1% in the first quarter. C WorldWide Group Holding A S now owns 1,950,049 shares of the medical research company’s stock worth $299,527,000 after buying an additional 1,772,300 shares during the period. Veritas Asset Management LLP increased its stake in Thermo Fisher Scientific by 112.4% in the second quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock worth $424,095,000 after buying an additional 1,286,259 shares during the period. Harbour Capital Advisors LLC increased its stake in Thermo Fisher Scientific by 18,197.5% in the second quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock worth $6,884,000 after buying an additional 1,194,487 shares during the period. Finally, Vanguard Group Inc. increased its stake in Thermo Fisher Scientific by 2.7% in the first quarter. Vanguard Group Inc. now owns 25,971,301 shares of the medical research company’s stock worth $3,989,193,000 after buying an additional 695,079 shares during the period. Institutional investors and hedge funds own 87.15% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Thermo Fisher Scientific Inc (NYSE:TMO) Receives Average Recommendation of “Buy” from Brokerages” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/08/11/thermo-fisher-scientific-inc-nysetmo-receives-average-recommendation-of-buy-from-brokerages.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.